Ipsen: completes acquisition of Albireo Pharma

(CercleFinance.com) - Ipsen has announced that it has completed the acquisition of Albireo Pharma, a leading innovator in the field of bile acid modulators for the treatment of rare liver diseases, an acquisition that it announced in January.


This acquisition enhances Ipsen's portfolio with promising treatments for rare cholestatic liver diseases, innovative products that have real development potential, as well as scientific and commercial capabilities.

As part of the deal, Ipsen is acquiring all of Albireo's issued and outstanding shares at a price of $42 per share in cash, plus a non-transferable guaranteed value certificate (GVC) of $10 per share.



Copyright (c) 2023 CercleFinance.com. All rights reserved.